Astellas Pharma Inc
OTC:ALPMY
Astellas Pharma Inc
OTC:ALPMY
Price:
16.06
USD
-3.02%
Market Closed
Market Cap:
$28.8B
Relative Value
The Relative Value of one
ALPMY
stock under the Base Case scenario is
13.48
USD.
Compared to the current market price of 16.06 USD,
Astellas Pharma Inc
is
Overvalued by 16%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
ALPMY
Relative Value
Base Case
13.48
USD
Overvaluation 16%
Multiples Across Competitors
ALPMY Competitors Multiples
Astellas Pharma Inc Competitors
Astellas Pharma Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| JP |
|
Astellas Pharma Inc
OTC:ALPMY
|
4.5T USD | 2.2 | 13.9 | 7.7 | 11.5 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
986.4B USD | 15.1 | 47.7 | 32.2 | 34.2 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
586.1B USD | 6.2 | 21.9 | 15.2 | 18.6 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
286.3B CHF | 4.7 | 30.5 | 12.9 | 15 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
235.3B GBP | 5.5 | 31.3 | 17.3 | 24.3 | |
| CH |
|
Novartis AG
SIX:NOVN
|
239B CHF | 5.5 | 22 | 13.6 | 17.4 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
301.2B USD | 4.6 | 16.5 | 10.3 | 12.1 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.4T DKK | 4.5 | 13.5 | 9.9 | 11.6 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 333.1 | 835.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
157.3B USD | 2.5 | 20.2 | 7.5 | 10 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
123.4B USD | 2.6 | 17.5 | 6.8 | 8.8 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
